

Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
You can purchase shares of Enliven Therapeutics (NASDAQ:ELVN) through any online brokerage.
Other companies in Enliven Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Enliven Therapeutics has a consensus price target of $67.54.
The stock price for Enliven Therapeutics (NASDAQ: ELVN) is $49.75 last updated November 6, 2026 at 7:58 PM EST.
There are no upcoming dividends for Enliven Therapeutics.
Enliven Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Enliven Therapeutics.
Enliven Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL...